Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal decision profile

Cancer Epidemiology Biomarkers & Prevention

Medicine
American Association for Cancer ResearchUnited StatespISSN 1055-9965eISSN 1538-7755
Checking system sharing availability.Visit homepage
Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
0.8

Journal Metrics Score 2026 · 20212024 window citedness 0.94.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
124 daysmedian

Middle 50%: 100153 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
Not available

No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
0.82026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#20 / 1,143LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
6.1%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.82MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
124 daysIQR 100–153 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
743 / yr2021–2024 AVG
Field-normalized top 10% share6.1%

181 of 2,971 works · same type, year & subfield

Field-normalized top 1% share0.2%

7 works · same type, year & subfield

Median FWCI0.82×

Below field-year expectation

Source output rank#20

of 1,143 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.82, so its typical recent paper runs about 18% below its field benchmark.

What does Top 10% Share mean?

6.1% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 20162025

5402016
5922017
5142018
2742019
16822020
4312021
5822022
11942023
7642024
8642025

Recent work-type mix

2,971 OpenAlex works · 20212024

Conference abstract63.2%
Article35.6%
Review0.8%
Paratext0.1%
Editorial0.1%
Erratum0.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works
Breast NeoplasmsNeoplasmsColorectal NeoplasmsProstatic NeoplasmsLung NeoplasmsEarly Detection of CancerCancer SurvivorsPapillomavirus InfectionsUterine Cervical Neoplasms

Leading OpenAlex topics

20212024 works
Global Cancer Incidence and Screening349
Cervical Cancer and HPV Research190
Cardiovascular Health and Risk Factors157
Colorectal Cancer Screening and Detection99
Cancer Risks and Factors96
Economic and Financial Impacts of Cancer74
Childhood Cancer Survivors' Quality of Life59
Prostate Cancer Treatment and Research52
BRCA gene mutations in cancer51
Cancer Genomics and Diagnostics51
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 2,971 works published 20212024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
OncologyQ4
EpidemiologyQ4

Considering submitting to Cancer Epidemiology Biomarkers & Prevention?

Use your manuscript title to find AI-ranked journals with related recent work, fit reasons, risks, and submission strategy.

Match my manuscript →
Q4
Subfield Quartile
B3
CAS Block

Ranking and source check

#724
of 853 Oncology field journals
#14
among Q4 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
13,886
H-Index
212
Fully Open Access
No
Recent OA Works
5,263
Subject Areas
OncologyOncologyOncologyEpidemiology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

Back to Search